Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas

Diabetes Care

Volumn 19, Issue 8, 1996, Pages 857-863

  Gutniak, Mark K ^a   Juntti Berggren, Lisa ^a   Hellström, Per M ^b   Guenifi, Amel ^a   Holst, Jens J ^c   Efendic, Suad ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; ISOPHANE INSULIN; PARACETAMOL; SULFONYLUREA DERIVATIVE;

ADULT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; ISOLATED PANCREAS ISLET; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; RAT; STOMACH EMPTYING; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029799525     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.8.857     Document Type: Article

References (29)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii: 1300-1303, 1987
2. Creutzfeldt W, Nauck MA: Gut hormones and diabetes mellitus. Diabete Metab Rev 8:149-177, 1992
3. Gutniak MK, Orskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1(7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
4. Nathan DM, Schreiber E, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
5. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
6. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide-1 abolishes postprandial glycemia in non-insulin dependent diabetes. Diabetes Care 17: 1039-1044, 1994
7. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-I (proglucagon 78-107 amide) from distal gut: role in regulation of gastric and pancreatic functions. Digestion 46 (Suppl. 1):120, 1990
8. Heading RC, Nimmo J, Prescott LF, Tothill P: The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmac 47:415-421, 1973
9. Hugget AS, Nixon DA: Use of glucose oxidase peroxidase and O-dianisidine in determination of blood and urinary glucose. Lancet ii:368-370, 1957
10. Simon M, Cuan J: Haemoglobin Alc isoelectric focusing. Clin Chem 28:9-12, 1982
11. Gennaro WE, Van Norman ID: Quantitation of free, total and antibody bound insulin in insulin-treated diabetics. Clin Chem 21:873-879, 1975
12. Holst JJ Bersani M: Assays for the peptide products of somatostatin gene expression. In Methods in Neurosciences, Vol 5: Peptides. Conn PM, Ed. New York, Academic Press, 1991, p. 3-22
13. Orskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma from non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1982
14. Holst JJ: Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residue 33-69) of glicemin. Biochem J 207:381-388, 1982
15. Orskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415-423, 1991
16. Habener JF: The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 1993 Dec 22:775-794, 1994
17. Östenson C, Grill V, Nylen A, Efendic S: Modulation by IBMX, fasting and experimental diabetes of glibenclamide-induced islet hormone release from the perfused rat pancreas. Diabete Metab 9:58-65, 1983
18. Arkhammar P, Nilsson T, Rorsman P, Berggren P: Inhibition of ATP-regulated K+ channels precedes depolarization-induced increase in cytoplasmic free Ca2+ concentration in pancreatic B-Cells. J Biol Chem 262:5448-5454, 1987
19. Holz IV GG, Kuhtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature 361:362-365, 1993
20. Abdel-Halim SM, Guenifi A, Östenson C, Efendic S: GLP-I (7-36)amide, GIP and forskolin elicit powerful insulinotropic responses at 3.3 mM glucose in GK rat model in NIDDM (Abstract). Diabetologia 37:A42, 1994
21. Henquin J: The interplay between cyclic AMP and ions in the stimulus-secretion coupling in pancreatic B-cells. Arch Intern Physiol Biochim 93:37-48, 1985
22. Eddlestone GT, Oldham SB, Lipson LG, Premdas FH, Beigelman PM: Electrical activity, cAMP concentration, and insulin release in mouse islets of Langerhans. Am J Physiol 248:C145-C153, 1985
23. Ämmälä C, Ashcroft FM, Rorsman P: Calcium-independent potentiation of insulin release by cyclic AMP in single beta-cells. Nature 363:356-358, 1993
24. Rajan AS, Hill RS, Boyd AE: Effect of rise in cAMP levels on Ca2+ influx through voltage-dependent Ca2+ channels in HIT cells: second-messenger synarchy in beta-cells. Diabetes 38:874-880, 1989
25. Yada T, Itoh K, Nakata M: Glucagon-like peptide-1 (7-36)amide and a rise in cyclic adenosine 3′,5′-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity. Endocrinology 133:1685-1692, 1993
26. Fehmann HC, Habener JF: Functional receptors for the insulinotropic hormone glucagon-like peptide 1(7-37) on somatostatin secreting cell line. FEBS Lett 279: 335-340, 1995
27. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-I (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
28. Frazer RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J: Hyperglycemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33:675-680, 1990
29. Eliasson B, Björnsson E, Urbanavicius V, Andersson H, Fowelin J, Attvall S, Abrahamsson H, Smith U: Hyperinsulinaemia impairs gastrointestinal motility and slows carbohydrate absorption. Diabetologia 38:79-85, 1995